AXA Framlington has appointed Andy Smith to run its Biotech fund from April.
Smith, who will report to the firm’s CEO, Robert Kyprianou, joins from venture capitalist SV Life Sciences where he managed its International Biotechnology trust.
SV has announced David Pinniger, a former Morgan Stanley analyst, will come in to replace Smith.
Before joining SV, Smith managed the Bioscience investment trust for five years, initially at 3i and then at Schroders when the trust transferred management house in 2004. In total, his investment career spans 30 years.
Kyprianou says: “Andy’s extensive experience in the global pharmaceutical industry and his impressive track record in managing biotechnology funds makes him an invaluable addition to the AXA Framlington healthcare team.
“The AXA Framlington Biotech fund and the AXA Framlington Health fund continue to enjoy excellent performance, increasing 59.86% and 45.27% over five years respectively to 29 February.
“Andy’s appointment, which follows the recruitment of Gemma Game to the healthcare team last year, demonstrates our continued commitment to this specialist sector.”
020 7034 2636
Brexit uncertainty a major factor
Highlights of group's 2018 Analyst Survey
Market smelt blood
Four days to go …
Improving portfolio diversification